Bronger Ingeham and CDR-Life develop antibody-based fragment therapy

May 14, Grigg Ingham and CDR-Life announced that they had reached a partnership and licensing agreement to jointly research and develop antibody-based fragment-based therapies for the treatment of map-like atrophy (GA). GA is an aggressive, irreversible retinal disease that occurs in age-related macular degeneration (AMD) patients and currently has no targeted treatment. The two companies will combine Grigg Ingham's expertise in the development of biologic therapies with CDR-Life's strong technology in antibody engineering to develop CDR-Life's preclinical candidate drugs with a view to preserving vision for GA patients.Using antibody fragment-based techniques, antibody specificity can be preserved while significantly reducing molecular size. Compared with traditional polymer drugs, antibody fragment-based therapy is expected to gain significant advantages in the treatment of retinal diseases. The high affinity antibody fragment drug is injected into the eye through the glass cavity and touches the epithelial cells of the retinal pigment known to be denatured. This precise technique can help reduce cellular pressure caused by AMD and prevent further loss of vision.Bronger Ingeham uses a holistic strategy to develop new retinal disease therapies, focusing on key mechanisms in the pathogenesis of retinal disease. By harnessing existing expertise in oncology, inflammation, neurodegenerative diseases, fibrosis, and heart metabolic diseases, the company has established a comprehensive portfolio of next-generation retinal therapies that are at various stages of development, with macular degeneration and diabetic retinal disease in Phase II clinical studies.CDR-Life's preclinical program uses antibody fragment-based technology to provide an innovative way to treat GA, complementing Grigg Ingham's growing portfolio.Under the terms of this agreement, Grigg Ingeham will be granted a global exclusive license to develop multiple compounds based on CDR-Life technology for specific targets and will be responsible for global development and commercialization. CDR-Life will be eligible for up to CHF 474.5 million in advance and milestone payments, as well as research funding and sales share. (U.S. News Agency)